Title: Immunitybio, Inc. (IBRX) 10K Annual Reports & 10Q SEC Filings
URL: https://last10k.com/sec-filings/ibrx

HOME


LOGIN


PREMIUM


FREE TRIAL


SEC FILINGS


STOCK SCREENERS


EARNINGS


TRENDING


STOCKTWITS


INSIDER TRADING


SENTIMENT ANALYSIS


MANAGER PORTFOLIOS


LATE CORPORATE NEWS






				 



Immunitybio, Inc. (IBRX) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023


Home
SEC Filings
Immunitybio, Inc. (IBRX)
10-K Annual Report Tue Mar 19 2024






SEC Filings



 
IBRX Valuations





Intrinsic Value





Financial Stability





Financial Ratios





Insider Trades





Manager Portfolios





Notifications





 
IBRX Annual Reports
				  





10-K Annual Report March 2024


PDF

PDF


Select PDF Feature:
Include Exhibits
Highlight YoY Changes
Highlight Sentiment

10-K Only


Word
Excel
CSV


Table of Contents
Business
Risk Factors
Unresolved Staff Comments
Cybersecurity
Properties
Legal Proceedings
Mine Safety Disclosures
Issuer Purchases of Equity Securities
Reserved
Managements Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Directors, Executive Officers and Corporate Governance
Executive Compensation
Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accountant Fees and Services
Exhibits and Financial Statement Schedules
Form 10K Summary
Signatures








									10-K Annual Report March 2023																






									10-K Annual Report March 2022																






IBRX Quarterly Reports
				  





									10-Q Quarterly Report August 2024																






									10-Q Quarterly Report May 2024																






									10-Q Quarterly Report November 2023																






									10-Q Quarterly Report August 2023																






									10-Q Quarterly Report May 2023																






									10-Q Quarterly Report November 2022																






									10-Q Quarterly Report August 2022																






									10-Q Quarterly Report May 2022																






									10-Q Quarterly Report November 2021																






									10-Q Quarterly Report August 2021																






IBRX Corporate News
				  





									New Agreement																	July 2024







									Financial ExhibitVote of Security Holders																	June 2024







									Financial ExhibitOther EventsRegulated Disclosure																	April 2024







									Code of Ethics ChangeEvent for Officers																	February 2024







									Financial ExhibitNew AgreementNew Financial ObligationOther EventsUnregistered Sales																	January 2024







									Financial ExhibitNew AgreementNew Financial ObligationOther EventsUnregistered Sales																	September 2023







									Financial ExhibitOther Events																	September 2023







									Financial ExhibitOther Events																	August 2023







									Financial ExhibitNew Agreement																	July 2023







									Financial ExhibitOther Events																	July 2023













Last10K.com | 10-K Annual Report Tue Mar 19 2024






Immunitybio, Inc.


													CIK: 1326110
																										Ticker: IBRX




10-K Annual Report Summary
 10-K Annual Report
 10-K YoY Changes
 Annual Proxy




Immunitybio, Inc.

HISTORY
TOOLS


CIK: 1326110
Ticker: IBRX




Cover Page - USD ($) $ in Millions12 Months EndedDec. 31, 2023Mar. 14, 2024Jun. 30, 2023Cover [Abstract]   Document Type10-K  Document Annual Reporttrue  Document Period End DateDec. 31,  2023  Current Fiscal Year End Date--12-31  Document Transition Reportfalse  Entity File Number001-37507  Entity Registrant NameIMMUNITYBIO, INC.  Entity Incorporation, State or Country CodeDE  Entity Tax Identification Number43-1979754  Entity Address, Address Line One3530 John Hopkins Court  Entity Address, City or TownSan Diego  Entity Address, State or ProvinceCA  Entity Address, Postal Zip Code92121  City Area Code844  Local Phone Number696-5235  Title of 12(b) SecurityCommon Stock, par value $0.0001 per share  Trading SymbolIBRX  Security Exchange NameNASDAQ  Entity Well-known Seasoned IssuerNo  Entity Voluntary FilersNo  Entity Current Reporting StatusYes  Entity Interactive Data CurrentYes  Entity Filer CategoryNon-accelerated Filer  Entity Small Businesstrue  Entity Emerging Growth Companyfalse  ICFR Auditor Attestation Flagfalse  Document Financial Statement Error Correction [Flag]false  Entity Shell Companyfalse  Entity Public Float  $ 315.9Entity Common Stock, Shares Outstanding 673,952,278 Documents Incorporated by ReferenceDOCUMENTS INCORPORATED BY REFERENCEAs noted herein, the information called for by Part III of this Annual Report is incorporated by reference to specified portions of the registrant’s definitive proxy statement to be filed in conjunction with the registrant’s 2024 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2023.  Amendment Flagfalse  Document Fiscal Year Focus2023  Document Fiscal Period FocusFY  Entity Central Index Key0001326110  

 

Please wait while we load the requested 10-K report or click the link below:https://last10k.com/sec-filings/report/1326110/000132611024000037/ibrx-20231231.htm


View differences made from one year to another to evaluate Immunitybio, Inc.'s financial trajectory





Sample 10-K Year-over-Year (YoY) Comparison



Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Immunitybio, Inc..

Continue







Assess how Immunitybio, Inc.'s management team is paid from their Annual Proxy





Screenshot example of actual Proxy Statement




Immunitybio, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors


Continue














SEC Filing Tools




 Sentiment
 Sections
 Exhibits
 Stats


 



 Rating					
Learn More










Filter Sentiment:



All






Positive




Negative





Filter Category:




All





Financial







Legal






Revenue






Mgmt Change






M & A






Other






Filter Subcategory:




All






Debt






Product






Expense






Cash Flow






Shares






Geography






Income






Other







 Inside Immunitybio, Inc.'s 10-K Annual Report:


 Financial - Debt   Highlight
The incurrence of additional indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.



 Other - Other   Highlight
Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that any ongoing pandemic could have on our significant accounting estimates.

 Legal - Other   Highlight
We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or the range of potential losses disclosed.

 Revenue - Product   Highlight
Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0 million paid on closing, less certain transaction expenses.

 Revenue - Product   Highlight
Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0 million paid on closing, less certain transaction expenses.

 Revenue - Product
A significant increase or decrease...Read more

 Legal - Other
•incur additional legal, accounting and...Read more

 Financial - Expense
In addition, we expect our...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
We have incurred net losses...Read more

 Financial - Expense
In anticipation of the commercialization...Read more

 Financial - Cash Flow
We have historically experienced negative...Read more

 Financial - Expense
Research and development expense decreased...Read more

 Financial - Expense
This transaction generated net proceeds...Read more

 Financial - Expense
This transaction generated net proceeds...Read more

 Financial - Shares
At the Effective Time, each...Read more

 Other - Other
Certain of our investments are...Read more

 Financial - Expense
The process of conducting clinical...Read more

 Financial - Debt
Furthermore, if prevailing interest rates...Read more

 Financial - Cash Flow
These risks could materially adversely...Read more

 Other - Other
A performance obligation is a...Read more

 Financial - Expense
Personnel costs, including salaries, benefits,...Read more

 Financial - Expense
We expect our research and...Read more

 Financial - Expense
We expect our research and...Read more

 Financial - Expense
Selling, general and administrative expense...Read more

 Revenue - Product
A contract’s transaction price is...Read more

 Revenue - Geography
However, after our entry into...Read more

 Financial - Expense
We expect that our selling,...Read more

 Financial - Expense
Major components of research and...Read more

 Other - Other
•In addition, we have contractual...Read more

 Revenue - Product
We currently estimate variable consideration...Read more

 Mgmt Change - Other
Effective October 3, 2023, we exercised...Read more

 Mgmt Change - Other
Effective August 31, 2023, we executed...Read more

 Other - Other
The allocation of the purchase...Read more

 Other - Other
The company’s external and internal resources...Read more

 Other - Other
The company’s external and internal resources...Read more

 Other - Other
Research and development data are...Read more

 Financial - Shares
Personnel of related companies who...Read more

 Financial - Expense
Additionally, the write down of...Read more

 Legal - Other
The rise in expenses was...Read more

 M & A - Other
Our investments in property, plant...Read more

 M & A - Other
Our investments in property, plant...Read more

 Financial - Expense
•cost of building, staffing and...Read more

 Other - Other
More specifically, the pandemic may...Read more

 Other - Other
We believe there is potential...Read more

 Financial - Debt
The effective interest rate is...Read more

 Other - Other
Also, in connection with the...Read more

 Financial - Shares
During February 2023, we filed a...Read more

 Other - Other
We believe that our innovative...Read more

 Revenue - Product
We recognize revenue when customers...Read more

 Revenue - Product
Since our inception, we have...Read more

 Financial - Expense
•time and cost necessary to...Read more

 Other - Other
The company received net proceeds...Read more

 Revenue - Product
We have generated revenues from...Read more

 Other - Other
Additionally, we believe that data...Read more

 Other - Other
We believe we are well...Read more

 Revenue - Product
We have primarily generated revenues...Read more

 Other - Other
We base our estimates on...Read more

 Financial - Debt
The increase in fair value...Read more

 Financial - Expense
•A $2.1 million decrease in equipment,...Read more

 Financial - Shares
During the year ended December 31, 2023,...Read more

 Revenue - Product
Upfront payments and fees are...Read more

 Other - Other
We have concluded that these...Read more

 Financial - Shares
At the Effective Time, each...Read more

 Other - Other
Further late-stage efforts for Anktiva...Read more

 Revenue - Product
In the future, cumulative worldwide...Read more

 M & A - Other
This amounts totals $60.8 million and...Read more

 Other - Other
Moreover, we record gain contingencies...Read more

 M & A - Other
As a result, all of...Read more

 Other - Other
Impairment of intangible assets increased...Read more

 Other - Other
We received net proceeds of...Read more

 Other - Other
However, given the continuously evolving...Read more

 Revenue - Product
From inception through the date...Read more

 Revenue - Product
From inception through the date...Read more

 M & A - Other
On March 9, 2021, we completed the...Read more

 M & A - Other
Contingent consideration incurred in connection...Read more

 Other - Other
We continue to monitor the...Read more

 Financial - Shares
Pursuant to the terms of...Read more

 Other - Other
We will need to obtain...Read more

 Revenue - Product
In connection with the RIPA,...Read more

 Financial - Shares
The noteholder has the sole...Read more

 Financial - Expense
In addition, subject to obtaining...Read more

 Other - Other
On October 26, 2023, we announced that...Read more

 Other - Other
On October 26, 2023, we announced that...Read more

 Financial - Shares
The noteholder has the sole...Read more

 Other - Other
The financial terms of these...Read more

 Other - Other
We also have sold our...Read more

 Other - Other
The company received net proceeds...Read more

 Other - Other
The terms of an embedded...Read more

 Financial - Expense
Other expense, net increased $155.7 million...Read more

 Financial - Expense
•employee-related expenses, including salaries, benefits,...Read more

 Other - Other
These platforms have generated 9 novel...Read more

 Revenue - Product
Unless and until we can...Read more

 Revenue - Product
•interest and principal payments on...Read more

 Financial - Shares
We measure the fair value...Read more

 Other - Other
•continue research and development, including...Read more

 Financial - Expense
Selling, general and administrative expense...Read more

 Other - Other
We expect to accelerate our...Read more

 Other - Other
The FDA requested that the...Read more

 Mgmt Change - Other
The Clinic is a related...Read more

 Other - Other
The $0.7 million write off of...Read more

 Financial - Expense
Grant revenue is typically paid...Read more

 Financial - Shares
All Tranche 2 principal amount of...Read more

 Financial - Expense
Payments made under these arrangements...Read more

 Other - Other
The goal of this potentially...Read more

 Other - Other
We are an integrated clinical-stage...Read more

 Financial - Expense
Additionally, there was a total...Read more

 Revenue - Product
We have no clinical products...Read more

 Revenue - Product
We have no clinical products...Read more

 Other - Other
Changing circumstances may cause us...Read more

 Other - Other
On December 29, 2023, we entered into...Read more

 Other - Other
The general condition of the...Read more

 Revenue - Product
•In connection with our 2017...Read more

 Other - Other
This embedded derivative will be...Read more

 Financial - Expense
Moreover, research and development and...Read more

 Other - Other
The arrangements typically include delivery...Read more

 Other - Other
On October 23, 2023, we announced that...Read more

 Other - Other
On October 23, 2023, we announced that...Read more

 Financial - Expense
Included in research and development...Read more

 Financial - Shares
Other expense, net consists primarily...Read more

 Financial - Expense
If the actual timing of...Read more

 Other - Other
We may also enter into...Read more

 Revenue - Product
As of December 31, 2023, Dr. Soon-Shiong and...Read more

 Other - Other
Under our license agreements with...Read more

 Revenue - Product
We may be required to...Read more

 Revenue - Product
From inception through the date...Read more

 Revenue - Product
We have typically invested our...Read more

 Other - Other
In addition to N-803, we...Read more

 M & A - Other
The Merger represents a business...Read more

 Other - Other
Our ultimate goal is to...Read more

 Revenue - Product
•We are obligated to make...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
On September 11, 2023, the company...Read more

 Other - Other
In May 2022, we announced the...Read more

 Other - Other
•hire clinical, manufacturing, scientific and...Read more

 M & A - Other
The Merger Agreement provided that...Read more

 Financial - Expense
For awards subject to performance-based...Read more

 Mgmt Change - Other
In June 2023, we exercised the...Read more

 Other - Other
We anticipate that we will...Read more

 Other - Other
Our platforms and their associated...Read more

 Other - Other
We record accruals for loss...Read more

 Other - Other
This includes conducting preclinical studies...Read more

 Other - Other
In addition, data from multiple...Read more

 Other - Other
•We have contractual obligations to...Read more

 Other - Other
We used the net proceeds...Read more

 Revenue - Product
There can be no assurance...Read more

 Other - Other
We used the net proceeds...Read more

 Other - Other
The outstanding principal amount and...Read more

 Other - Other
This is due to the...Read more

 Other - Other
If we determine that a...Read more

 Other - Other
•We are obligated to make...Read more

 Other - Other
We have only one product...Read more

 Other - Other
In 2021, we completed a...Read more

 Financial - Debt
Debt amendments that are considered...Read more

 Other - Other
On June 13, 2023, the company executed...Read more

 Revenue - Product
Oberland also has an option...Read more

 Revenue - Product
Oberland also has an option...Read more

 Other - Other
There can be no assurance...Read more

 Other - Other
Our lead biologic commercial product...Read more

 Other - Other
On March 31, 2023, the company executed...Read more

 Revenue - Product
On a quarterly basis, we...Read more

 Other - Other
We do not expect any...Read more

 Financial - Expense
The company imputes interest expense...Read more

 Financial - Debt
“Financial Statements and Supplementary Data”...Read more

 Financial - Debt
“Financial Statements and Supplementary Data”...Read more

 Financial - Shares
Also, on December 29, 2023 and in...Read more

 Financial - Shares
Also, on December 29, 2023 and in...Read more

 Other - Other
The accrued interest on any...Read more

 Other - Other
On December 29, 2023 in connection with...Read more

 Other - Other
As part of our resubmission,...Read more

 Other - Other
Under the FVO election, the note...Read more

 M & A - Other
Following the consummation of the...Read more

 Financial - Shares
The conversion price was determined...Read more

 Other - Other
The fair value of the...Read more

 Financial - Shares
On September 11, 2023, the company...Read more

 Financial - Expense
Other selling, general and administrative...Read more

 Financial - Shares
We may also seek to...Read more

 Financial - Shares
Based on the terms of...Read more

 M & A - Other
On December 21, 2020, NantKwest and NantCell...Read more

 Other - Other
As of December 31, 2023, we had...Read more

 Other - Other
We anticipate that strategic collaborations...Read more

 Financial - Debt
Embedded derivatives that are required...Read more

 Other - Other
In addition, if our aggregate...Read more

 Financial - Expense
The company’s external research and development...Read more

 Financial - Expense
The company’s external research and development...Read more

 Revenue - Product
We may prepay the outstanding principal...Read more

 Revenue - Product
Given the high degree of...Read more

 Financial - Expense
•our ability to successfully commercialize...Read more

 Other - Other
We are also obligated to...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 M & A - Other
We may need to seek...Read more

 Other - Other
•We have certain contractual commitments...Read more

 Other - Other
Additionally, we record our rights...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Financial - Income
We are subject to U.S. federal...Read more

 Revenue - Product
The license agreements may include...Read more

 Revenue - Product
However, we may be unable...Read more

 Financial - Expense
When evaluating the adequacy of...Read more

 Financial - Expense
These increases were partially offset...Read more

 Other - Other
Without additional funds, we may...Read more

 Financial - Debt
The company evaluates amendments to...Read more

 Financial - Expense
Research and development expense consists...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
Further, because of the numerous...Read more

 Financial - Cash Flow
In instances where the net...Read more

 Other - Other
We accrue for the best...Read more

 Other - Other
These statements are based on...Read more

 Other - Other
This assessment, which requires the...Read more

 Other - Other
The COVID-19 pandemic continues to...Read more

 Financial - Shares
For warrants that do not...Read more

 Other - Other
The CRL did not request...Read more

 Revenue - Geography
Additionally, if and when we...Read more

 Revenue - Product
The company evaluates the interest...Read more

 Financial - Shares
In addition, the amendment allows...Read more

 Other - Other
Using our proprietary platforms that...Read more

 Financial - Expense
We estimate clinical trial and...Read more

 Financial - Expense
The reduction in costs were...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
On December 29, 2023 in connection with...Read more

 Other - Other
As a result, we may...Read more

 Other - Other
The company may prepay the...Read more

 Financial - Expense
We allocate expenses associated with...Read more

 Other - Other
Affiliates of NantWorks are also...Read more

 Other - Other
As a result of continuing...Read more

 Financial - Expense
•progress, timing, number, scope and...Read more

 Other - Other
At the time, the FDA...Read more

 Other - Other
The Black-Scholes option pricing model...Read more

 Legal - Other
This includes instances when our...Read more

 Other - Other
Specifically, our clinical focus includes...Read more

 Financial - Expense
•expenses incurred under agreements with...Read more

 Other - Other
In addition, the RIPA contains...Read more

 Other - Other
◦The $200.0 million convertible promissory note...Read more

 Revenue - Product
Revenue increased $0.4 million during the...Read more

 Other - Other
On December 29, 2023 in connection with...Read more

 M & A - Other
Business combinations are accounted for...Read more

 Financial - Income
From inception through December 31, 2023, we...Read more

 Other - Other
Significant judgments and estimates are...Read more

 Financial - Expense
We have incurred and expect...Read more

 Other - Other
•establish a commercialization infrastructure and...Read more

 M & A - Other
•terms, timing and costs of...Read more

 Financial - Debt
Gains and losses on debt...Read more

 Other - Other
We account for stock-based compensation...Read more

 Financial - Expense
The company classifies its research...Read more

 Financial - Expense
The company classifies its research...Read more

 Other - Other
In addition, the company entered...Read more

 Other - Other
On September 11, 2023, the company...Read more

 Other - Other
Our current license and collaboration...Read more

 Revenue - Product
In addition, Oberland may purchase...Read more

 Other - Other
◦The $30.0 million convertible promissory note...Read more

 Revenue - Product
We do not expect to...Read more

 Financial - Shares
These changes were partially offset...Read more

 Revenue - Product
The interest rate on this...Read more

 Other - Other
These payments may not be...Read more

 Financial - Expense
Substantially all of our net...Read more

 Financial - Expense
The company’s internal research and development...Read more

 Financial - Expense
The company’s internal research and development...Read more

 Other - Other
We have entered into multiple...Read more

 Financial - Shares
The assessment considers whether the...Read more

 Revenue - Product
Pursuant to the RIPA, Oberland...Read more

 Revenue - Product
•revenue from product candidates that...Read more

 Other - Other
We estimate fair value of...Read more

 Other - Other
•We are obligated to make...Read more

 Other - Other
Our Executive Chairman, Global Chief...Read more

 Other - Other
On May 9, 2023, the FDA delivered...Read more

 Other - Other
On May 9, 2023, the FDA delivered...Read more

 Other - Other
On September 11, 2023, the company...Read more

 Other - Other
The nonexclusive license agreements with...Read more

 Other - Other
This note was accounted for...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
“Financial Statements and Supplementary Data”...Read more

 Other - Other
•potential additional safety monitoring or...Read more

 Legal - Other
During the year ended December 31, 2021,...Read more

 Other - Other
The Tranche 2 of the promissory...Read more

 Revenue - Product
We may prepay the outstanding...Read more

 M & A - Other
These standards require that the...Read more

 Financial - Debt
Legal fees and other costs...Read more

 M & A - Other
•In connection with the acquisitions...Read more

 Other - Other
The event-based milestone payments represent...Read more

 Other - Other
However, we may not be...Read more

 Financial - Expense
At this time, we cannot...Read more

 Financial - Debt
Amounts paid by the company...Read more

 Other - Other
While we believe the BLA...Read more

 Other - Other
The company accounted for a...Read more

 Financial - Shares
On July 20, 2023, we entered...Read more

 Financial - Debt
In instances where the net...Read more

 Other - Other
Changes in fair values reflect...Read more

 Financial - Shares
On September 11, 2023, the company and...Read more

 Revenue - Product
Under the RIPA, Oberland has...Read more

 Revenue - Product
Under the RIPA, Oberland has...Read more

 Revenue - Product
Under the RIPA, Oberland has...Read more

 Other - Other
In accruing clinical and research-related...Read more

 Financial - Debt
Prior to its extinguishment on...Read more

 Other - Other
As a result of the...Read more

 Revenue - Product
These agreements generally include upfront...Read more

 Other - Other
All material intercompany accounts and...Read more

 Financial - Expense
•A $5.1 million increase in external...Read more

 Other - Other
Through the date of this...Read more

 Other - Other
The deficiencies in the CRL...Read more

 Financial - Expense
•A $7.3 million decrease in personnel-related...Read more

 Other - Other
Although we do not expect...Read more

 Other - Other
If we raise additional funds...Read more

 Legal - Other
•costs of filing, prosecuting, maintaining,...Read more

 Other - Other
In addition, the terms of...Read more

 Financial - Expense
We have also incurred and...Read more

 Financial - Expense
For awards with service or...Read more

 Other - Other
As a result of the...Read more

 Other - Other
Pursuant to the terms of...Read more

 Financial - Shares
During the year ended December 31, 2023,...Read more

 Financial - Shares
To the extent that we...Read more

 Financial - Expense
We generally classify our operating...Read more

 Other - Other
This includes personnel in executive,...Read more

 Revenue - Product
If we fail to complete...Read more



 
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report





Audit Information





Cover Page





Consolidated Balance Sheets





Consolidated Balance Sheets (Parenthetical)





Consolidated Statements Of Cash Flows





Consolidated Statements Of Comprehensive Loss





Consolidated Statements Of Operations





Consolidated Statements Of Stockholders' Deficit





Consolidated Statements Of Stockholders' Deficit Parenthetical)





Collaboration And License Agreements And Acquisition





Collaboration And License Agreements And Acquisition (Tables)





Collaboration And License Agreements And Acquisition - Acquisition (Details)





Collaboration And License Agreements And Acquisition - Acquisition - Additional Information (Details)





Collaboration And License Agreements And Acquisition - Collaboration Agreements - Additional Information (Detail)





Collaboration And License Agreements And Acquisition - License Agreements - Additional Information (Detail)





Commitments And Contingencies





Commitments And Contingencies - Contingent Consideration Related To Business Combinations - Additional Information (Detail)





Commitments And Contingencies - Litigation - Additional Information (Detail)





Commitments And Contingencies - Unconditional Purchase Obligations (Details)





Description Of Business





Description Of Business (Tables)





Description Of Business - Additional Information (Details)





Description Of Business - Schedule Of Impact Of Change In Reporting Entity On Unaudited Condensed Consolidated Statements Of Operations (Detail)





Employee Benefits





Employee Benefits (Details)





Fair Value Measurements





Fair Value Measurements (Tables)





Fair Value Measurements - Additional Information (Details)





Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail)





Financial Instruments





Financial Instruments (Tables)





Financial Instruments - Accumulated Unrealized Losses On Debt Securities Classified As Available-For-Sale In Continuous Loss Position (Detail)





Financial Instruments - Additional Information (Detail)





Financial Instruments - Available-For-Sale Marketable Debt Securities (Detail)





Financial Statement Details





Financial Statement Details (Tables)





Financial Statement Details - Accrued Expenses And Other Liabilities (Detail)





Financial Statement Details - Additional Information (Detail)





Financial Statement Details - Intangible Assets, Net (Details)





Financial Statement Details - Interest And Investment Income (Loss), Net (Detail)





Financial Statement Details - Interest Expense (Details)





Financial Statement Details - Prepaid Expenses And Other Current Assets (Detail)





Financial Statement Details - Property, Plant And Equipment, Net (Detail)





Income Taxes





Income Taxes (Tables)





Income Taxes - Additional Information (Detail)





Income Taxes - Changes To Unrecognized Tax Benefits (Details)





Income Taxes - Components Of Income Tax Benefit (Provision) (Details)





Income Taxes - Deferred Tax Assets And Liabilities (Details)





Income Taxes - Loss Before Taxes, Domestic And Foreign (Details)





Income Taxes - Reconciliation Of Federal Statutory Income Tax Rate To Effective Income Tax Rate (Details)





Lease Arrangements





Lease Arrangements (Tables)





Lease Arrangements - Additional Information (Detail)





Lease Arrangements - Components Of Lease Expense (Detail)





Lease Arrangements - Schedule Of Cash Paid For Amounts Included In Measurement Of Lease Liabilities (Detail)





Lease Arrangements - Summary Of Future Minimum Lease Payments (Detail)





Lease Arrangements - Summary Of Information Regarding Leases (Detail)





Lease Arrangements - Supplemental Balance Sheet Information (Details)





Related Party Debt - Estimated Fair Value Of Convertible Note (Details)





Related Party Debt - Related Party Promissory Notes (Details)





Related-Party Agreements





Related-Party Agreements (Tables)





Related-Party Agreements - Additional Information (Detail)





Related-Party Agreements - Outstanding Balances Of Related-Party Agreements (Detail)





Related-Party Debt





Related-Party Debt (Tables)





Related-Party Debt - Additional Information (Details)





Related-Party Debt - Estimated Material Contractual Obligations Related To Related-Party Promissory Notes (Details)





Related-Party Debt - Summary Of Related-Party Promissory Notes (Detail)





Revenue Interest Purchase Agreement





Revenue Interest Purchase Agreement (Tables)





Revenue Interest Purchase Agreement - Additional Information (Details)





Revenue Interest Purchase Agreement - Summary Of The Revenue Interest Liability Activity (Details)





Stock-Based Compensation





Stock-Based Compensation (Tables)





Stock-Based Compensation - Additional Information (Detail)





Stock-Based Compensation - Rsu Activity Under Equity Plans (Detail)





Stock-Based Compensation - Stock Option Activity And Related Information Under Equity Plans (Detail)





Stock-Based Compensation - Stock-Based Compensation Expenses Related To Statement Of Operations (Detail)





Stock-Based Compensation - Weighted Average Fair Value Of Options Under Black-Scholes Option Pricing Model (Detail)





Stockholders' Deficit - Additional Information (Detail)





Stockholders??? Deficit





Summary Of Significant Accounting Policies





Summary Of Significant Accounting Policies (Policies)





Summary Of Significant Accounting Policies (Tables)





Summary Of Significant Accounting Policies - Additional Information (Details)





Summary Of Significant Accounting Policies - Estimated Useful Lives Of Property, Plant And Equipment (Details)





Summary Of Significant Accounting Policies - Revenue By Geographic Region (Details)





Summary Of Significant Accounting Policies - Securities Excluded From The Computation Of Potentially Dilutive Securities (Detail)





Warrant Liabilities





Warrant Liabilities (Details)




 
Material Contracts, Statements, Certifications & more
Immunitybio, Inc. provided additional information to their SEC Filing as exhibits





Exhibit 4.7: Instruments Defining The Rights Of Security Holders, Including Indentures





Exhibit 10.3: Material Contract





Exhibit 10.4: Material Contract





Exhibit 10.5: Material Contract





Exhibit 10.13: Material Contract





Exhibit 10.17: Material Contract





Exhibit 10.41: Material Contract





Exhibit 21.1: Subsidaries Of The Registrant





Exhibit 23.1: Consents Of Experts And Counsel





Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 32.1: Section 1350 Certification





Exhibit 32.2: Section 1350 Certification





Exhibit 97.1: Ex-97.1






Ticker: IBRX CIK: 1326110
Form Type: 10-K Annual Report
Accession Number: 0001326110-24-000037
Submitted to the SEC: Tue Mar 19 2024 4:31:53 PM EST
Accepted by the SEC: Tue Mar 19 2024
Period:  Sunday, December 31, 2023
Industry: Biological Products No Disgnostic Substances						
External Resources:
 Stock Quote
 Social Media
 SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/ibrx/0001326110-24-000037.htm








About 
											Contact 
											Help 
											API 
											Privacy 
											Terms 
									


© 2012 - 2024 Last10K.com All Rights Reserved









×
You're Signed Out
Sign in for the full experience


Sign in
Join Now








Intrinsic Value Calculator








Screenshot of intrinsic value for AT&T (2019)




Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
Continue












Never Miss A New SEC Filing Again








Screenshot taken from Gmail for a new 10-K Annual Report




Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news
Continue












We Highlighted This SEC Filing For You








Screenshot taken from Wynn's 2018 10-K Annual Report




Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q
Continue












Widen Your SEC Filing Reading Experience








Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report




Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view
Continue












Uncover Actionable Information Inside SEC Filings








Screenshot taken from Lumber Liquidators 10-K Annual Report




Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Financial Stability Report








Screenshot of financial stability report for Coco-Cola (2019)




Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
Continue












Get a Better Picture of a Company's Performance








Available Financial Ratios




Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years
Continue












See when company executives buy or sell their own stock








Screenshot taken from Euronet (EEFT)




Last10K.com Member Feature

Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings
Continue












See how institutional managers trade a stock








Screenshot taken from General Motors (GM)




Last10K.com Member Feature

View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more
Continue












FREE Financial Statements








Screenshot of actual balance sheet from company 10-K Annual Report




Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREE












SEC Filing Exhibit
 PDF Download



Loading SEC Filing Exhibit...








SEC Filing Financial Summary
 PDF Download
 Excel Download



Loading SEC Filing Financial Summary...

